The estimated Net Worth of Michele Ollier is at least $22 Million dollars as of 10 August 2016. Michele Ollier owns over 1,000,000 units of Minerva Neurosciences Inc stock worth over $11,983,686 and over the last 10 years Michele sold NERV stock worth over $10,000,000.
Michele has made over 3 trades of the Minerva Neurosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Michele sold 1,000,000 units of NERV stock worth $10,000,000 on 10 August 2016.
The largest trade Michele's ever made was buying 1,620,833 units of Minerva Neurosciences Inc stock on 7 July 2014 worth over $9,724,998. On average, Michele trades about 705,867 units every 191 days since 2014. As of 10 August 2016 Michele still owns at least 4,488,272 units of Minerva Neurosciences Inc stock.
You can see the complete history of Michele Ollier stock trades at the bottom of the page.
Michele's mailing address filed with the SEC is C/O MINERVA NEUROSCIENCES, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE, MA, 02142.
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over $49,043,620 worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth $47,876,311 . The most active insiders traders include & Johnson Johnson & Johnson..., Venture Associates Iii Ltd ..., and Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $556,476. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth $105,193.
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include: